12:00 AM
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Other News

Innovative Medicines Initiative (IMI) infectious news

The EU's Innovative Medicines Initiative said it launched two projects under its New Drugs for Bad Bugs (ND4BB) antimicrobial resistance research program. The Combating Bacterial Resistance in Europe (COMBACTE) program will receive €194.6 million ($260.4 million) and will focus on combining academic and industry researchers to generate innovative...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >